Frontiers in Clinical Drug Research. Volume 7, CNS and Neurological Disorders.

Cover -- Title -- Copyright -- Contents -- Preface -- List of Contributors -- Emerging Innovative Therapies of Spinal Muscular Atrophy: Current Knowledge and Perspectives -- Tai-Heng Chen1,2,3,* and Ching H. Wang4,5 -- INTRODUCTION -- CLINICAL CHARACTERISTICS OF SMA -- Phenotypes and Classifications of SMA -- The Implication of Phenotypic Classification in SMA Clinical Trials -- IMPACTS OF EVOLVING SUPPORTIVE CARE IN SMA THERA- PEUTIC ERA -- RECENT ADVANCES IN INNOVATIVE THERAPEUTICS IN SMA: FOCUSING ON SMN AND BEYOND -- SMN-DEPENDENT THERAPIES FOR SMA

Previous SMN-Targeted Clinical Trials with Equivocal Outcomes -- Nusinersen: The First Approved Splicing-Modify Therapy for SMA -- Gene Therapy for SMA: SMN1 Gene Replacement -- Other Small-Molecule SMN Splicing Modifiers -- Risdiplam (RG7916) -- Branaplam (LMI070) -- Celecoxib -- Quinazoline (Repligen RG3039) -- Full-Length SMN Protein Stabilizer -- SMN-INDEPENDENT THERAPIES FOR SMA -- Neuroprotective Agents -- Myostatin Inhibitors -- Skeletal Muscle Troponin Activator: Reldesemtiv -- Agents Targeting Neuromuscular Junction, Synapse, or Neurotransmitter -- Pyridostigmine -- 4-aminopyridine

Stem Cells Therapy -- COMBINATION THERAPY FOR SMA -- CONCLUSIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Obesity Induced by the Neurological Drugs -- Semiha Kurt*, Orhan Sumbul, Betul Cevik and Durdane Aksoy -- INTRODUCTION -- Antiepileptic Drugs (AEDs) -- Valproic Acid (VPA) -- Gabapentin (GBP) -- Felbamate -- Lamotrigine (LTG) -- Pregabalin (PGB) -- Topiramate (TPM) -- Zonisamide (ZNS) -- Carbamazepine (CBZ) -- Oxcarbazepine (OXC) -- Vigabatrin (VGB) -- Levetiracetam (LEV) -- Possible Causes of Antiepileptics Induced Weight Gains -- Antipsychotics

Pimavanserin -- Clozapine -- Quetiapine -- Olanzapine -- Possible Causes of Weight Gain Caused by Antipsychotics -- Antidepressants -- Tricyclic Antidepressants -- Selective Serotonin Reuptake Inhibitors (SSRIs) -- Selective Serotonin-Noradrenaline Reuptake Inhibitors (SNRIs) -- Beta-Blockers -- Calcium Channel Blockers -- Serotonergic / Histaminergic Agents -- Glucocorticoids -- Dopaminergic Drugs -- CONCLUDING REMARKS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Molecular Mechanism of Nervous System Disorders and Implications for New Therapeutic Targets

Farhin Patel and Palash Mandal* -- NERVOUS SYSTEM DISORDERS -- Infectious Disorders -- Meningitis -- Epigenetics: -- Functional Disorders -- Epilepsy -- Cytokines Involved in Epilepsy: -- Neuralgia -- (A). Peripheral Nerve Injury -- (B). Central Nerve Injury -- Gene Therapy: -- Epigenetics: -- Structural Disorder -- Bell's Palsy (Idiopathic Facial Paralysis) -- Guillain-Barré Syndrome (GBS) -- Degenerative Disorder -- Huntington's Disease -- Therapeutic Approaches: -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES

Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of central nervous system (CNS) and other nerve disorders. The scope of the book series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of contemporary molecular targets involved in neurological and CNS disorders. Reviews presented in the series are mainly focused on clinical and therapeutic aspects of novel drugs intended for.

eBooks on EBSCOhost EBSCO eBook Subscription Academic Collection - Worldwide